Physician profile
Elliot E Cazes
NPI 1629042460
$725,156.96
in general payments reported to CMS, 2019-2025
21 companies · $109K in 2025
The $109K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $75K · 2021: $151K · 2022: $116K · 2023: $128K · 2024: $120K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $265K · Travel and Lodging: $37K · Honoraria: $22K · Food and Beverage: $21K · Consulting Fee: $12K · Education: $112 · Gift: $2.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $265,000.00 |
| Travel and Lodging | $37,277.77 |
| Honoraria | $22,435.00 |
| Food and Beverage | $20,679.29 |
| Consulting Fee | $11,500.00 |
| Education | $112.35 |
| Gift | $2.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $293,452.81 | 2022-2025 | |
| Abbvie INC. | $240,299.15 | 2019-2022 | |
| Myovant Sciences INC. | $104,892.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $45,119.72 | 2023-2025 | Myfembree |
| Ascend Therapeutics US, LLC | $23,015.66 | 2023-2025 | |
| Pfizer INC. | $14,121.52 | 2021-2022 | |
| Scynexis, INC. | $3,590.29 | 2022 | |
| Astellas Pharma US INC | $230.30 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $112.29 | 2019-2022 | |
| Roche Diagnostics Corporation | $59.96 | 2019-2021 | |
| Evofem Biosciences, INC. | $55.56 | 2021 | |
| Millicent US INC | $47.48 | 2024-2025 | Femlyv |
| Hologic Sales and Service, LLC | $28.74 | 2021 | |
| Lilly USA, LLC | $27.01 | 2020 | |
| Shield Therapeutics INC | $22.82 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $20.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Avion Pharmaceuticals | $14.60 | 2021 | |
| Lupin INC. | $14.18 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $12.44 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Cazes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.